Latest News Archive

Please select Category, Year, and then Month to display items

KovsieX breaking new frontiers

07 January 2025 | Story Gerda-Marie van Rooyen | Photo Supplied

Optimising student experience while providing students with multimedia training using state-of-the-art equipment and aligning with Vision 130, KovsieX is set to become a great asset to the university, its students, and the community.

This initiative, approved by the UFS Rectorate on 29 November 2023, combines various student media brands on the Bloemfontein and Qwaqwa campuses (KovsieFM, Q-Lit, KovsieTV, KovsieCAST) into a unified brand consisting of three student-driven sub-departments. This includes audio (radio and podcasts), video (long and short form), and social media (including TikTok, Instagram, WhatsApp, and YouTube).

An all-digital approach

Gerben van Niekerk, Head of Student Experience (KovsieX), explains: “This all-digital approach leverages digital radio, podcasts, and social media platforms to create a sense of belonging among students by reflecting on and leading student life across the campuses.” KovsieX has achieved remarkable success, reaching an audience of more than 1,2 million in the first semester alone, with multiple TikTok videos surpassing 100 000 views.

“Recognising the evolving radio landscape, our approach integrates a comprehensive digital strategy to adapt to changing media consumption preferences and provide students with hands-on experience on emerging platforms, strengthening their market relevance. KovsieX (previously KovsieFM) moves away from traditional FM broadcasting and has enabled the students to cover a wider range of topics that affect the Kovsie community,” says Van Niekerk. He adds, “The essence of KovsieX can be summarised in our one-word slogan: IMAGINE.”

KovsieX supports Vision 130, as it leverages emerging technologies to enrich academic and non-academic student experiences. Furthermore, it also provides students with the opportunity to gain on-the-job and leadership experience in the KovsieX executive committee (KovsieXco), comprising a small group of ‘dynamic and highly talented students’, with their first objective: to decide on a brand name and setting on KovsieX – with the ‘X’ referring to experience.

A mobile app provides students with easier access to KovsieX’s content. This initiative is set to increase students’ experience even more, as possible partnerships are in the pipeline to deliver a year-long dialogue series on themes pertinent to students. “This initiative will engage students on key issues such as leadership, mental health, heritage, and anti-discrimination through a blend of digital content – including interviews, social media posts, and expert discussions – and live on-campus events.”

State-of-the-art facilities

The construction of the KovsieX Pod on the Bloemfontein Campus allows students to produce content in a state-of-the-art podcast and video studio with Apple Mac workstations and a meeting room. A similar space in the current Student Media Building on the Qwaqwa Campus, named the KovsieX Q-Pod, is on the cards, as is the integration of KovsieX across the Bloemfontein and Qwaqwa campuses. “KovsieX will be broadcast from two locations and will, therefore, allow students from both campuses to interact with one another live on air. Both radio studios will be rebuilt to allow students to stream directly on YouTube, Instagram, and TikTok from both campuses simultaneously. This is made possible by cutting edge cloud-based software – popular in Europe – but KovsieX will be the first to leverage this technology in the country,” shares Van Niekerk.

News Archive

Cardiology Unit involved in evaluation of drug for rare genetic disease

2013-01-04

Front from the left, are: Marinda Karsten (study coordinator and registered nurse),
Laumarie de Wet (clinical technologist), Charmaine Krahenbuhl (study coordinator and radiographer),
Lorinda de Meyer (administrator), Andonia Page (study coordinator and enrolled nurse);
back Dr Gideon Visagie (sub investigator), Dr Derick Aucamp (sub investigagtor),
Prof. Hennie Theron, (principal investigator) and Dr Wilhelm Herbst (sub investigator).
Photo: Supplied
09 January 2013

The Cardiology Research Unit at the University of the Free State (UFS) contributed largely to the evaluation of the drug Juxtapid (lomitapide), which was developed by the Aegerion pharmaceutical company and approved by the FDA (Federal Drug Administration). Together with countries such as die USA, Canada and Italy, the UFS’ Unit recruited and evaluated the most patients (5 of 29) for the study since 2008.

The drug was evaluated in persons with so-called familial homozygous hypercholesterolemia (HoFH).

Following its approval by the FDA, Juxtapid is now a new treatment option for patients suffering from HoFH. The drug operates in a unique way which brings about dramatic improvements in cholesterol counts.

According to Prof. Hennie Theron, Associate Professor in the Department of Cardiology at the UFS and Head of the Cardiology Contract Research Unit, HoFH is a serious, rare genetic disease which affects the function of the receptor responsible for the removal of low-density lipoprotein cholesterol (LDL-C) (“bad” cholesterol) from the body. Damage to the LDL receptor function leads to extremely high levels of blood cholesterol. HoFH patients often develop premature and progressive atherosclerosis, which is a narrowing or blockage of the arteries.

“HoFH is a genetically transmitted disease and the most severe form of hypercholesterolemia. Patients often need a coronary artery bypass or/and aortic valve replacement before the age of 20. Mortality is extremely high and death often occurs before the third decade of life. Existing conventional cholesterol-lowering medication is unsuccessful in achieving normal target cholesterol values in this group of patients.

“The only modality for treatment is plasmapheresis (similar to dialysis in patients with renal failure). Even with this type of therapy the results are relatively unsatisfactory because it is very expensive and the plasmapheresis has to be performed on a regular basis.

“The drug Juxtapid, as currently evaluated, has led to a dramatic reduction in cholesterol values and normal values were achieved in several people. No existing drug is nearly as effective.

“The drug represents a breakthrough in the treatment of familial homozygous hypercholesterolemia. The fact that it has been approved by the FDA, gives further impetus to the findings,” says Prof. Theron.

In future further evaluation will be performed in other forms of hypocholesterolemia.

According to Prof. Theron, the findings of the study, as well as the recent successful FDA evaluation, once again confirms the fact that the UFS’ Cardiology Contract Research Unit is doing outstanding work.

Since its inception in 1992, the Unit has already been involved in more than 60 multi-centre, international phase 2 and 3 drug studies. Several of these studies, including the abovementioned study, really affected the way in which cardiology functions.

The UFS’ Cardiology Contract Research Unit is being recognised nationally and internationally for its high quality of work and is constantly approached for their involvement in new studies.

Back

Economic and Management Sciences

Education

Health Sciences

The Humanities

Law

Natural and Agricultural Sciences

Theology and Religion

Open Distance Learning

Business School

We use cookies to make interactions with our websites and services easy and meaningful. To better understand how they are used, read more about the UFS cookie policy. By continuing to use this site you are giving us your consent to do this.

Accept